Condensed Consolidated Statements Of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Cash Flows from Operating Activities
Net income (loss)	$ 16,112	$ (4,568)
Adjustments to Reconcile Net Income (Loss) to Net Cash Provided by Operating Activities:
Depreciation and amortization	9,202	8,955
Gain on sale of bioplastics manufacturing business	0	(1,453)
Gains on property insurance recoveries	(1,223)	0
Release of valuation allowance	(1,215)	0
Share based compensation	588	970
Equity method investment (earnings) loss	(7,287)	962
Changes in Operating Assets and Liabilities:
Restricted cash	0	12
Receivables, net	(3,729)	3,529
Inventory	3,452	(342)
Prepaid expenses	(587)	(541)
Refundable income taxes	241	16
Accounts payable	(8,188)	(509)
Accounts payable to affiliate, net	2,220	(3,491)
Accrued expenses	(295)	1,478
Deferred credit	334	(340)
Accrued retirement health and life insurance benefits and other noncurrent liabilities	(456)	(680)
Other	(414)	6
Net cash provided by operating activities	8,755	4,004
Cash Flows from Investing Activities
Additions to property and equipment	(4,920)	(3,571)
Proceeds from sale of bioplastics manufacturing business	0	2,797
Proceeds from property insurance recoveries	1,383	0
Other	4	0
Net cash used in investing activities	(3,533)	(774)
Cash Flows from Financing Activities
Purchase of treasury stock	(601)	0
Payment of dividends	(907)	(916)
Principal payments on long-term debt	(1,162)	(1,288)
Proceeds from revolving credit facility	49,590	83,031
Payments on revolving credit facility	(54,933)	(84,057)
Loan fees incurred with borrowings	(66)	0
Net cash used in financing activities	(8,079)	(3,230)
Decrease in cash and cash equivalents	(2,857)	0
Cash and cash equivalents, beginning of year	2,857	0
Cash and cash equivalents, end of period	$ 0	$ 0